查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1981455

药物发现资讯学市场：按组件、治疗领域、应用、最终用户和部署模式划分－2026-2032年全球市场预测

Drug Discovery Informatics Market by Component, Therapeutic Area, Application, End User, Deployment - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，药物发现资讯学市场价值将达到 35.1 亿美元，到 2026 年将成长到 38.8 亿美元，到 2032 年将达到 69.5 亿美元，复合年增长率为 10.21%。

主要市场统计数据
基准年 2025 35.1亿美元
预计年份：2026年 38.8亿美元
预测年份 2032 69.5亿美元
复合年增长率 (%) 10.21%

药物发现资讯学的发展以及组织为整合计算平台和服务而应采取的策略重点架构。

药物资讯学融合了计算科学、生物学和转化研究，重塑了治疗假设的生成、检验和推进方式。生物资讯学和化学资讯学的创新正在拓展In Silico方法的范围和精确度，使研究团队能够以前所未有的深度分析基因组、蛋白质组和化学领域。此外，相关服务能够将平台输出转换为可操作的工作流程，并透过咨询、系统整合和持续支持，确保模型输出与实验室执行之间的衔接。

识别技术、服务和管治的融合趋势，这些趋势正在重塑整个研究生态系统中的药物发现资讯学和伙伴关係模式。

药物发现资讯学领域正经历着一场变革性的转变，其驱动力来自调查方法的成熟、平台整合以及云端原生运算范式的普及。基于多组体学资料集训练的机器学习模型如今已常规地与基于物理的模拟相结合，分子对接、QSAR建模和虚拟筛检技术的通量和预测精度也得到了显着提升。此外，对可重复性和可解释性的日益重视进一步强化了这些技术进步，促使供应商和研究团队加强对Provence（一种模型检验框架）和透明性能基准的投入。

本研究评估了 2025 年与关税相关的贸易变化将如何影响药物研发专案中的供应商多元化、合约创新和策略部署选择。

2025年美国关税环境造成了多层次的商业性不确定性，将影响采购、供应商策略和国际合作。在硬体、专用运算设备和某些软体相关服务与跨境贸易密切相关的领域，关税促使各组织重新评估其筹资策略和整体参与成本。实际上，采购团队正在扩大供应商范围，纳入国内供应商和区域合作伙伴，一些组织还在协商签订多年期合同，以应对未来关税变化带来的影响。

我们按组件、应用、部署模型、最终用户和治疗领域进行细分，以识别差异化的部署模式和策略机会领域。

细分市场分析阐明了功能和需求如何在组件、应用、部署模式、最终用户和治疗领域中分布，揭示了不同的部署模式和功能缺口。从组件来看，市场由「服务」和「软体」两部分组成。 「服务」包括咨询、系统整合、支援和维护等功能，这些功能弥合了平台功能与实验室操作之间的差距。 「软体」则分为生物资讯学和化学资讯学。在生物资讯学领域，基因组资讯学、蛋白质组学和转录组学分别反映了不同的数据模式和分析需求。同时，在化学资讯学领域，分子对接、QSAR建模和虚拟筛检是支援化合物优先排序和虚拟先导化合物发现的融合方法。

本报告将揭示区域管理体制、人才库和基础设施现状如何影响全球部署选择、伙伴关係和合作模式。

区域趋势，以及各自独特的监管环境、人才储备和基础设施考量，正在影响各组织部署资讯学解决方案和建立伙伴关係的方式。在美洲，对转化研究的大力投入、生物製药公司总部的高度集中以及成熟的云端运算和高效能运算（HPC）能力，正在推动整合生物资讯学和化学资讯学平台的快速普及。这种环境强调互通性和供应商生态系统，以支援学术机构和商业伙伴之间的复杂合作，并实现跨机构的端到端发现工作流程。

本分析探讨了平台供应商、整合商、服务供应商和研究合作伙伴如何建构能力和合作伙伴关係，以提供端到端的药物发现解决方案。

在药物资讯学领域运作的公司正在平台开发、服务交付和整合伙伴关係展现出差异化的能力。成熟的软体供应商专注于建立强大且检验的生物资讯学和化学资讯学工具链，并投资于模组化架构，使客户能够整合基因组学、蛋白质组学和分子建模的结果。同时，越来越多的专业公司正在利用机器学习和基于实体的模型来提高ADMET预测、虚拟筛检和基于结构的药物设计方面的预测性能，并经常与大型整合商合作，以服务企业客户。

为了加快发现流程，领导者需要建立可互通的平台，平衡部署风险，并采取切实可行的策略措施来加强模型管治。

产业领导者应采取一系列切实有效的措施，调整组织能力以适应不断变化的资讯学需求，并确保策略柔软性。首先，应优先考虑互通架构和标准化资料模型，以便在无需大规模重新设计的情况下整合新工具。这将减少供应商锁定，并加速跨职能工作流程。其次，应采用混合部署策略，兼顾本地资源的安全性和控制力以及云端环境的弹性运算和协作优势。这种方法允许团队将敏感资料工作流程分配到託管环境中，同时利用公共云端进行运算密集型模拟。

本文描述了一种混合方法研究途径，该方法结合了相关人员访谈和二手研究，以得出检验的见解和明确的限制。

本分析的调查方法结合了多方面的质性研究和结构化的综合分析，旨在得出引人注目且切实可行的见解。主要研究包括对製药和生物技术公司、受託研究机构(CRO)、平台供应商和学术研究机构的关键相关人员进行访谈，重点关注采购行为、采用决策、整合挑战和治疗领域优先事项。这些访谈旨在了解从业人员对功能、挑战和策略权衡的观点，参与者包括计算科学家、研发 (R&D) 负责人和营运经理。

将调查方法、商业性和营运因素综合起来，形成对电脑辅助药物发现和转化研究未来的洞察和结论。

累积分析凸显了该领域的发展演变。调查方法的进步、平台的成熟以及商业性动态的转变正在重塑药物发现的概念化和实施方式。资讯学能力不再只是辅助工具，而是假设生成和候选化合物筛选的核心驱动力，软体平台和服务之间的交互作用决定了组织将计算科学洞见转化为实际应用的程度。商业性因素，例如区域和关税方面的考量，对采购政策和部署架构施加了实际限制，而按应用和治疗领域进行细分则有助于明确哪些投资领域能够带来最大的科学和营运回报。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 药物发现资讯学市场：依组成部分划分

  • 服务
    • 咨询
    • 一体化
    • 支援和维护
  • 软体
    • 生物资讯学
      • 基因组资讯学
      • 蛋白质体学资讯学
      • 转录组学资讯学
    • 化学资讯学
      • 分子对接
      • QSAR建模
      • 虚拟筛检

第九章：药物发现资讯学市场：依治疗领域划分

  • 心血管疾病
  • 感染疾病
  • 代谢性疾病
  • 神经科学
  • 肿瘤学

第十章 药物发现资讯学市场：依应用领域划分

  • ADMET预测
    • 代谢预测
    • 药物动力学预测
    • 毒性预测
  • 发现铅
    • 高通量筛检资讯学
    • 从爆款到爆款的资讯学
    • 虚拟筛检资讯学
  • 分子建模与模拟
    • 分子动力学
    • QSAR建模
    • 结构设计
  • 目标识别
    • 基因组分析
    • 蛋白质体学分析
    • 目标检验资讯学

第十一章 药物发现资讯学市场：以最终用户划分

  • 学术研究机构
  • 合约研究机构
  • 製药和生物技术公司

第十二章 药物发现资讯学市场：依发展领域划分

  • 云
  • 现场

第十三章 药物发现资讯学市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 药物发现资讯学市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 药物发现资讯学市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国药物发现资讯学市场

第十七章：中国药物发现资讯市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • BioSolveIT GmbH
  • Certara, Inc.
  • Clarivate PLC
  • Dassault Systemes SE
  • Dotmatics Ltd
  • Genedata AG
  • InSilico Medicine
  • International Business Machines Corporation
  • Jubilant Biosys Ltd.
  • Optibrium Ltd
  • Oracle Corporation
  • PerkinElmer Inc.
  • Schrodinger, Inc.
  • TIBCO Software Inc.
Product Code: MRR-521BAA36EBB5

The Drug Discovery Informatics Market was valued at USD 3.51 billion in 2025 and is projected to grow to USD 3.88 billion in 2026, with a CAGR of 10.21%, reaching USD 6.95 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.51 billion
Estimated Year [2026] USD 3.88 billion
Forecast Year [2032] USD 6.95 billion
CAGR (%) 10.21%

Framing the evolution of drug discovery informatics and the strategic priorities organizations must adopt to integrate computational platforms and services

Drug discovery informatics sits at the nexus of computational science, biology, and translational research, reshaping how therapeutic hypotheses are generated, validated, and advanced. Innovations in bioinformatics and cheminformatics have expanded the scope and precision of in silico approaches, enabling research teams to interrogate genomic, proteomic, and chemical spaces with unprecedented depth. These capabilities are complemented by services that translate platform outputs into deployable workflows, with consulting, systems integration, and ongoing support ensuring continuity between model outputs and laboratory execution.

Across organizations, this convergence is driving a shift in operational models: software platforms that once served as niche tools are now integral to discovery pipelines, while service providers are embedding advanced analytics into end-to-end solutions. As a result, cross-functional teams composed of computational scientists, bench researchers, and data engineers are becoming standard, fostering rapid iteration between hypothesis generation and empirical validation. In this context, leaders must prioritize interoperability, data provenance, and lifecycle management of computational models to preserve scientific rigor while accelerating time-to-experimentation. Understanding these dynamics is essential for stakeholders seeking to align capabilities with strategic goals and to navigate the competitive landscape of platform vendors, integrators, and research institutions.

Identifying the converging technological, service, and governance trends reshaping drug discovery informatics and partnership models across the research ecosystem

The landscape of drug discovery informatics is undergoing a transformative shift driven by methodological maturation, platform integration, and the mainstreaming of cloud-native compute paradigms. Machine learning models trained on multi-omic datasets are now routinely coupled with physics-based simulations, while molecular docking, QSAR modeling, and virtual screening methods have improved in throughput and predictive value. These technical gains are reinforced by a growing emphasis on reproducibility and explainability, prompting vendors and research groups to invest in provenance, model validation frameworks, and transparent performance benchmarks.

Concurrently, services ecosystems have evolved to provide not only implementation support but also strategic advisory roles. Consulting teams increasingly help organizations assess the fit of bioinformatics and cheminformatics solutions against internal capabilities, and integration experts orchestrate data flows between laboratory information management systems, high-performance computing resources, and cloud environments. The rise of hybrid deployment options allows organizations to balance data sensitivity with scalability, enabling secure on-premise processing for protected datasets and public cloud bursts for compute-intensive simulations. Taken together, these developments are reshaping partnership models between technology providers, contract research organizations, and end users, creating new pathways for innovation while raising the bar for governance and interoperability.

Assessing how tariff-related trade shifts in 2025 are prompting supplier diversification, contractual innovation, and strategic deployment choices in discovery programs

The United States tariff environment in 2025 introduced layers of commercial uncertainty that ripple across procurement, supplier strategies, and international collaborations. Where hardware, specialized computational appliances, and certain software-linked services intersect with cross-border trade, tariffs have prompted organizations to reassess sourcing strategies and total cost of engagement. In practice, procurement teams have expanded supplier panels to include domestic vendors and regional partners, and some organizations have negotiated multi-year agreements to protect against further tariff volatility.

These adjustments have implications for research timelines and capital planning. R&D leaders are increasingly evaluating the tradeoffs between acquiring on-premise infrastructure and adopting cloud-based alternatives that mitigate hardware import exposure. Similarly, partnerships with contract research organizations and platform providers are being structured to share risk, with clauses that address tariff-related cost changes and delivery contingencies. In addition, tariff-driven supply chain realignments have intensified interest in regionalized data processing and storage, both to reduce exposure and to meet evolving regulatory obligations. Ultimately, the cumulative impact of tariffs is less a single cost shock and more a stimulus for strategic supplier diversification, contractual innovation, and accelerated adoption of deployment models that decouple computational capacity from geopolitically sensitive hardware supply chains.

Unpacking component, application, deployment, end-user, and therapeutic area segmentation to reveal differentiated adoption patterns and strategic opportunity spaces

Segmentation analysis clarifies how capabilities and demand are distributed across components, applications, deployments, end users, and therapeutic areas, revealing differentiated adoption patterns and capability gaps. By component, the market comprises Services and Software; Services encompasses consulting, systems integration, and support and maintenance functions that bridge the gap between platform capabilities and laboratory operations, while Software divides into Bioinformatics and Cheminformatics. Within Bioinformatics, genomics informatics, proteomics informatics, and transcriptomics informatics reflect distinct data modalities and analytic requirements; within Cheminformatics, molecular docking, QSAR modeling, and virtual screening represent convergent methods that support compound prioritization and virtual hit discovery.

Application segmentation highlights how analytical techniques are applied: ADMET prediction spans metabolism, pharmacokinetics, and toxicity prediction workflows that inform early attrition mitigation; lead discovery combines high-throughput screening informatics, hit-to-lead processing, and virtual screening informatics to accelerate candidate selection; molecular modeling simulation includes molecular dynamics, QSAR modeling, and structure-based design used to refine candidates; and target identification blends genomic and proteomic analyses with target validation informatics to prioritize biological hypotheses. Deployment choices manifest as cloud and on-premise models; cloud offerings differentiate across hybrid cloud, private cloud, and public cloud options, while on-premise deployments range from client-server to enterprise server implementations. End users include academic research institutes, contract research organizations, and pharmaceutical and biotechnology companies, each exhibiting unique procurement behaviors, risk tolerances, and demands for customization. Therapeutic area segmentation spans cardiovascular disease, infectious disease, metabolic disorders, neuroscience, and oncology, reflecting both scientific complexity and investment focus. Understanding these segments in an integrated manner enables targeted capability development and market-facing strategies that align technological strengths with user needs and therapeutic priorities.

Mapping how regional regulatory regimes, talent concentrations, and infrastructure realities influence deployment choices, partnerships, and collaboration models globally

Regional dynamics are shaping how organizations deploy informatics solutions and structure partnerships, with each geography presenting distinct regulatory landscapes, talent pools, and infrastructure considerations. In the Americas, strong investment in translational research, a deep concentration of biopharma headquarters, and established cloud and HPC capacity combine to favor rapid adoption of integrated bioinformatics and cheminformatics platforms. This environment supports complex collaborations between academic centers and commercial partners, and it places a premium on interoperability and vendor ecosystems that can support end-to-end discovery workflows across diverse institutions.

Europe, the Middle East, and Africa present a heterogeneous mix of regulatory regimes and research ecosystems. In parts of Europe, stringent data protection and regional research funding frameworks encourage hybrid deployment models and strong emphasis on data governance. Meanwhile, pockets of innovation across the region drive demand for localized expertise and integration services that can adapt global platforms to regional research priorities. In the Asia-Pacific region, rapid expansion of biotech activity, sizable talent pools in computational biology and chemistry, and policy initiatives that prioritize innovation have catalyzed adoption of cloud-native solutions and public-private partnerships. However, organizations in this region also emphasize cost-efficiency and scalable deployment models that can accommodate fast-growing research portfolios. Across all regions, cross-border collaborations and virtualized research networks are increasing, creating new imperatives for standardized data exchange, compliance, and secure collaboration practices.

Profiling how platform vendors, integrators, service providers, and research partners are organizing capabilities and alliances to deliver end-to-end discovery solutions

Companies operating in the drug discovery informatics space exhibit differentiated capabilities across platform development, service delivery, and integrative partnerships. Established software vendors focus on building robust, validated toolchains for bioinformatics and cheminformatics, investing in modular architectures that enable customers to combine genomic, proteomic, and molecular modeling outputs. Simultaneously, a growing cohort of specialized firms leverages machine learning and physics-informed models to enhance predictive performance in ADMET prediction, virtual screening, and structure-based design, often partnering with larger integrators to reach enterprise customers.

Service-oriented organizations, including consulting firms and systems integrators, play a pivotal role in helping end users translate platform capabilities into operational workflows. These providers are extending offerings beyond tactical implementation to include model governance, data harmonization, and continuous performance monitoring. Contract research organizations are increasingly embedding informatics capabilities into trial and preclinical workflows, while academic spinouts contribute novel algorithms and domain expertise that accelerate scientific breakthroughs. Strategic alliances between platform vendors, cloud providers, and CROs are becoming more common, enabling bundled offerings that reduce integration friction for customers. Observed across the ecosystem is an emphasis on open interfaces, standardized data models, and partnership structures that distribute risk while preserving the capacity for rapid innovation.

Practical strategic moves for leaders to build interoperable platforms, balance deployment risks, and strengthen model governance to accelerate discovery pipelines

Industry leaders should pursue a set of pragmatic, high-impact actions to align organizational capabilities with emerging informatics demands and to protect strategic flexibility. First, prioritize interoperable architectures and standardized data models so that new tools can be integrated without extensive reengineering; this reduces vendor lock-in and accelerates cross-functional workflows. Second, adopt a hybrid deployment strategy that balances the security and control of on-premise resources with the elastic compute and collaboration benefits of cloud environments. This approach allows teams to allocate sensitive data workflows to controlled environments while leveraging public cloud for compute-intensive simulations.

Third, strengthen supplier diversification and contractual mechanisms to manage geopolitical and tariff-related risks. Include clauses that address cost adjustments and delivery contingencies, and cultivate regional supplier relationships where appropriate. Fourth, invest in workforce development by combining computational training for wet-lab scientists with domain education for data engineers, building multidisciplinary teams capable of iterating rapidly between models and experiments. Fifth, establish robust model governance frameworks that encompass validation protocols, provenance tracking, and performance monitoring, ensuring reproducibility and regulatory readiness. Finally, pursue targeted partnerships with academic centers and CROs to access specialized assays and validation pathways, thereby shortening the route from in silico prediction to empirically supported candidate progression.

Explaining the mixed-method research approach that integrates stakeholder interviews and secondary analysis to produce validated insights and transparent limitations

The research methodology underpinning this analysis combined multi-source qualitative inquiry with structured synthesis to produce defensible, actionable insights. Primary research included interviews with key stakeholders across pharmaceutical and biotechnology companies, contract research organizations, platform vendors, and academic research groups, focusing on procurement behavior, deployment decisions, integration challenges, and therapeutic area priorities. These engagements were designed to capture practitioner perspectives on capabilities, pain points, and strategic tradeoffs, and interview participants represented computational scientists, R&D leaders, and operations managers.

Secondary research reviewed technical literature, vendor documentation, and publicly available case studies to contextualize practitioner testimony and to validate technical trends. Data synthesis emphasized triangulation: where multiple independent sources converged on similar findings, confidence in the insight increased. Segmentation was applied along component, application, deployment, end-user, and therapeutic area dimensions to reflect how capabilities and demand differ across use cases. Limitations of the methodology include potential selection bias in stakeholder participation and the rapid pace of technological change that can outdate specific tool-level details; to mitigate these risks, the approach prioritized thematic patterns and structural dynamics that are robust across vendors and geographies. Ethical considerations guided the research, including anonymization of interview responses and adherence to consent protocols for proprietary information.

Concluding insights that synthesize methodological, commercial, and operational drivers shaping the future of computational discovery and translational research

The cumulative analysis highlights a field in motion: methodological advances, platform maturation, and shifting commercial dynamics are converging to reshape how drug discovery is conceptualized and executed. Informatics capabilities are no longer auxiliary tools but central enablers of hypothesis generation and candidate progression, and the interplay between software platforms and services determines the degree to which organizations can operationalize computational insights. Regional and tariff-driven commercial factors introduce practical constraints that influence procurement choices and deployment architectures, while segmentation by application and therapeutic area clarifies where investments will yield the greatest scientific and operational returns.

For research leaders and commercial strategists, the imperative is clear: prioritize modular, governed informatics ecosystems that support reproducibility, integrate with laboratory operations, and scale across deployment scenarios. By aligning talent, governance, and partnership strategies with technological advances, organizations can convert computational promise into experimentally validated therapeutics. Ultimately, success hinges on the ability to maintain scientific rigor while adopting adaptive procurement and deployment practices that absorb commercial volatility and accelerate translational progress.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug Discovery Informatics Market, by Component

  • 8.1. Services
    • 8.1.1. Consulting
    • 8.1.2. Integration
    • 8.1.3. Support And Maintenance
  • 8.2. Software
    • 8.2.1. Bioinformatics
      • 8.2.1.1. Genomics Informatics
      • 8.2.1.2. Proteomics Informatics
      • 8.2.1.3. Transcriptomics Informatics
    • 8.2.2. Cheminformatics
      • 8.2.2.1. Molecular Docking
      • 8.2.2.2. Qsar Modeling
      • 8.2.2.3. Virtual Screening

9. Drug Discovery Informatics Market, by Therapeutic Area

  • 9.1. Cardiovascular Diseases
  • 9.2. Infectious Diseases
  • 9.3. Metabolic Disorders
  • 9.4. Neuroscience
  • 9.5. Oncology

10. Drug Discovery Informatics Market, by Application

  • 10.1. Admet Prediction
    • 10.1.1. Metabolism Prediction
    • 10.1.2. Pharmacokinetics Prediction
    • 10.1.3. Toxicity Prediction
  • 10.2. Lead Discovery
    • 10.2.1. High Throughput Screening Informatics
    • 10.2.2. Hit To Lead Informatics
    • 10.2.3. Virtual Screening Informatics
  • 10.3. Molecular Modeling Simulation
    • 10.3.1. Molecular Dynamics
    • 10.3.2. Qsar Modeling
    • 10.3.3. Structure Based Design
  • 10.4. Target Identification
    • 10.4.1. Genomic Analysis
    • 10.4.2. Proteomic Analysis
    • 10.4.3. Target Validation Informatics

11. Drug Discovery Informatics Market, by End User

  • 11.1. Academic Research Institutes
  • 11.2. Contract Research Organizations
  • 11.3. Pharmaceutical Biotechnology Companies

12. Drug Discovery Informatics Market, by Deployment

  • 12.1. Cloud
  • 12.2. On Premise

13. Drug Discovery Informatics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Drug Discovery Informatics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Drug Discovery Informatics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Drug Discovery Informatics Market

17. China Drug Discovery Informatics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. BioSolveIT GmbH
  • 18.6. Certara, Inc.
  • 18.7. Clarivate PLC
  • 18.8. Dassault Systemes SE
  • 18.9. Dotmatics Ltd
  • 18.10. Genedata AG
  • 18.11. InSilico Medicine
  • 18.12. International Business Machines Corporation
  • 18.13. Jubilant Biosys Ltd.
  • 18.14. Optibrium Ltd
  • 18.15. Oracle Corporation
  • 18.16. PerkinElmer Inc.
  • 18.17. Schrodinger, Inc.
  • 18.18. TIBCO Software Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DRUG DISCOVERY INFORMATICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DRUG DISCOVERY INFORMATICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DRUG DISCOVERY INFORMATICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONSULTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONSULTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONSULTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INTEGRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INTEGRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INTEGRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SUPPORT AND MAINTENANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SUPPORT AND MAINTENANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SUPPORT AND MAINTENANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMICS INFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMICS INFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMICS INFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMICS INFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMICS INFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMICS INFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TRANSCRIPTOMICS INFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TRANSCRIPTOMICS INFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TRANSCRIPTOMICS INFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DOCKING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DOCKING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DOCKING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY NEUROSCIENCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY NEUROSCIENCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY NEUROSCIENCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLISM PREDICTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLISM PREDICTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLISM PREDICTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACOKINETICS PREDICTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACOKINETICS PREDICTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACOKINETICS PREDICTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TOXICITY PREDICTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TOXICITY PREDICTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TOXICITY PREDICTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIGH THROUGHPUT SCREENING INFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIGH THROUGHPUT SCREENING INFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIGH THROUGHPUT SCREENING INFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIT TO LEAD INFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIT TO LEAD INFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIT TO LEAD INFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING INFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING INFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING INFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DYNAMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DYNAMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DYNAMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY STRUCTURE BASED DESIGN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY STRUCTURE BASED DESIGN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY STRUCTURE BASED DESIGN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMIC ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMIC ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMIC ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET VALIDATION INFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET VALIDATION INFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET VALIDATION INFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLOUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLOUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLOUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ON PREMISE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ON PREMISE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ON PREMISE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 260. GCC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. GCC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 262. GCC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 263. GCC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 264. GCC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 265. GCC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 266. GCC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 267. GCC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 268. GCC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 269. GCC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 270. GCC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, 2018-2032 (USD MILLION)
  • TABLE 271. GCC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 272. GCC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. GCC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPEAN UNION DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPEAN UNION DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 289. BRICS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 290. BRICS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 293. BRICS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 294. BRICS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 295. BRICS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 296. BRICS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, 2018-2032 (USD MILLION)
  • TABLE 297. BRICS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 298. BRICS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, 2018-2032 (USD MILLION)
  • TABLE 299. BRICS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 300. BRICS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. BRICS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)